Eclipsys skips into black in Q2

Eclipsys logged a solid second quarter, ended June 30, with quarterly revenues of $134.4 million, compared to $129.8 million for the second quarter of 2009.

On a GAAP [generally accepted accounting principles] basis, net income for the second quarter of 2010 was $1.6 million, compared with net loss of $4.1 million in the second quarter of 2009, according to the Atlanta-based company.

For the six months that ended June 30, new business bookings were $259.4 million, as new and existing customers made investment decisions to meet the meaningful use criteria of the American Reinvestment and Recovery Act. The company said it defines new business bookings as the total amount of all new contracts signed, excluding renewal contracts.

Eclipsys ended the quarter with $143.3 million of cash and $37.3 million in long-term investments.

Around the web

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Trimed Popup
Trimed Popup